Dr. Guillermo de Velasco Oria de Rueda

Nº total: 42 indexadas en pubmed

Publicaciones más destacadas:

1. de Velasco G, et al. Cancer Immunol Res. 2016 Oct
2. Chen F et al. Cell Rep. 2016 Mar;
3. Albiges et al. JCO. 2016 Sep;
4. de Velasco G, et al. Cancer Immunol Res. 2016 Jan.
5. Sum et al. Jama Oncol, 2015.

Últimas 5 publicaciones:

1. Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs). Martini DJ, et al. Cancer Immunol Res. 2018 Feb 1. pii: canimm.0220.2017. doi: 10.1158/2326 6066.CIR-17-0220
2. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Viteri Malone MA, et al. Clin Genitourin Cancer. 2017 Dec 6. pii: S1558-7673(17)30365-8. doi: 10.1016/j.clgc.2017.11.005.
3. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. Sun M, De Velasco G, et al. Eur Urol Focus. 2018 Jan 5. pii: S2405-4569(17)30294-8. doi: 10.1016/j.euf.2017.12.007.
4. Urothelial cancer proteomics provides both prognostic and functional information.de Velasco G, et al. Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.
5. In Reply. de Velasco G, et al. Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. No abstract available.